EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer



RB1 and p53 at the crossroad of EMT and triple-negative breast cancer



Cell Cycle 10(10): 1563-1570



Triple-negative breast cancer (TNBC) is a heterogeneous disease that includes Basal-like and Claudin-low tumors. The Claudin-low tumors are enriched for features associated with epithelial-to-mesenchymal transition (EMT) and possibly for tumor initiating cells. Primary TNBCs respond relatively well to conventional chemotherapy; however, metastatic disease is virtually incurable. Thus, there is a great interest in identifying specific therapeutic targets for TNBC. The tumor suppressor RB1 is frequently lost in Basal-like breast cancer. To test for a causative role of RB1 gene loss in BC and for its effect on specific subtypes, we deleted mouse Rb in mammary stem/bipotent progenitor cells. This led to diverse mammary tumors including TNBC, with a subset of the latter containing p53 mutations and exhibiting features of Basal-like BC or EMT. Combined mutation of Rb and p53 in mammary stem/bipotent progenitors induced EMT type tumors. Here, we review our findings and those of others, which connect Rb and p53 to EMT in TNBC. Furthermore, we discuss how by understanding this circuit and its vulnerabilities, we may identify novel therapy for TNBC.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333557

Download citation: RISBibTeXText

PMID: 21502814

DOI: 10.4161/cc.10.10.15703



Related references

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care 10(6): 413-416, 2016

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data. Breast Cancer Research 16(6): 490-490, 2015

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. Tumour Biology 35(10): 9751-9757, 2015

Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer. Targeted Oncology 10(1): 85-97, 2015

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. Plos One 7(9): E45831-E45831, 2013

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. International Journal of Nanomedicine 10: 3937-3953, 2016

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Disease 32(1-2): 35-48, 2012

Diurnal periodicity of assimilate transport shapes resource allocation and whole plant carbon balance. Plant Journal, 2018

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3): 246-248, 2010

Triple- negative breast cancer ( triple - negative breast cancer ) - homogeneous or heterogeneous group of cancers ?. Polish Journal of Pathology 65(4 Suppl 2): S53-S61, 2015

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. Oncotarget 7(11): 13047-13059, 2016

Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer. Nan Fang Yi Ke Da Xue Xue Bao 31(10): 1729-1732, 2013

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biology & Therapy 14(6): 537-545, 2014

Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Medical Oncology 29(5): 3240-3249, 2013

MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. Plos One 9(11): E111877-E111877, 2015